Stockreport

Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024

Longeveron Inc. - Class A Common stock  (LGVN) 
PDF MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative med [Read more]